EN | CN

Elpiscience to Present Two Programs at The Society for Immunotherapy of Cancer (“SITC”) 2021 Annual Meeting

October 22 , 2021 17:00

Shanghai/Suzhou, China, and Maryland, US, October 22, 2021. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company focusing on discovering and developing next-generation cancer immunotherapies, today announced that the company would present two exciting innovations at the 36thSociety for Immunotherapy of Cancer (SITC) Annual Meeting, which will be taken place both in person and virtually in Washington, D.C. from November 10 to 14, 2021.


Elpiscience will present:

1) a novel bispecific macrophage engager platform, and

2) an innovative anti-CD39/TGFβ-Trap bispecific antibody

The poster presentations are scheduled both online and offline.


Details of the Poster presentations are as follows:


Title:

    A Novel Bispecific Macrophage Engager Antibody (BiME) Designed for Cancer Immunotherapy

Abstract No.:

    # 272

Session Date:

    7:00-20:00 EST, Nov. 12-14, 2021

First Author:

    Dr. Dawei Sun, Elpiscience

Presenter:

    Dr. Dawei Sun, Elpiscience

Title:

    Creating an Immune-favorable Tumor Microenvironment by A Novel Anti-CD39/TGFβ-Trap Bispecific Antibody (ES014)

Abstract No.:

    # 792

Session Date:

    7:00-20:00 EST, Nov. 12-14, 2021

First Author:

    Dr. Dawei Sun, Elpiscience

Presenter:

    Dr. Hongtao Lu, Elpiscience


About ES014:

ES014, a dual acting molecule that binds CD39 and TGF-β simultaneously, was designed by fusing the TGF-β Receptor-II ectodomain to an antibody targeting CD39. The bi-specific molecule inhibits ATPase activity, resulting in the inhibition of the generation of immune-suppressive adenosine and promotion of immune-stimulating ATP while at the same time it also neutralizes immunosuppressive factor, TGF-β, aiming to create an immune-favorable tumor microenvironment. It has been demonstrated that ES014 can block Treg differentiation and significantly promote the survival and function of Teff cells. ES014 achieved a strong single agent anti-tumor efficacy in a PD-1 unresponsive mouse model.


About BiME:

BiME, is a proprietary bi-specific macrophage engaging platform developed by Elpiscience. By utilizing a SIRPα inhibitory antibody as a macrophage engager and activator, we have linked it to an anti-tumor-associated-antigen (TAA) antibody to directly activate macrophage phagocytosis towards the particular TAA cancer. ES028, a bispecific antibody targeting CLDN18.2 and SIRPα, is a unique biotherapeutic candidate coming out of the BiME platform. ES028 has demonstrated promising therapeutic efficacy in a pre-clinical animal model with a favorable tolerability profile. Different BIME bi-specific antibodies are being developed, utilizing different TAA antibodies to target different cancer types.


About Elpiscience:

Elpiscience is a global-clinical stage biopharmaceutical company focusing on innovating and developing the next generation of cancer immunotherapy. Elpiscience has developed a pipeline of globally innovative molecules, covering a wide range of targets with a particular focus on turning “cold” tumors “hot”.  The company has four assets in clinical stage (ES104, ES101, ES102 and ES002). Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by renowned investors such as Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, Cormorant Asset Management and Superstring Capital. Elpiscience endeavors to advance at least one potentially innovative or differentiated global molecule into the clinic each year, providing clinical benefits to cancer patients worldwide.